|
1
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M,
Liu L, Liu C, Xu J, Gao YT, Zheng Y, et al: Cancer statistics:
Current diagnosis and treatment of pancreatic cancer in Shanghai,
China. Cancer Lett. 346:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh HM, Ungerechts G and Tsimberidou AM:
Gene and cell therapy for pancreatic cancer. Expert Opin Biol Ther.
15:505–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
White R, Rose K and Zon L: Zebrafish
cancer: The state of the art and the path forward. Nat Rev Cancer.
13:624–636. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Geiger GA, Fu W and Kao GD:
Temozolomide-mediated radio-sensitization of human glioma cells in
a zebrafish embryonic system. Cancer Res. 68:3396–3404. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berghmans S, Jette C, Langenau D, Hsu K,
Stewart R, Look T and Kanki JP: Making waves in cancer research:
New models in the zebrafish. Biotechniques. 39:227–237. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang B, Shimada Y, Kuroyanagi J,
Nishimura Y, Umemoto N, Nomoto T, Shintou T, Miyazaki T and Tanaka
T: Zebrafish xenotransplantation model for cancer stem-like cell
study and high-throughput screening of inhibitors. Tumour Biol.
35:11861–11869. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eser S, Schnieke A, Schneider G and Saur
D: Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer.
111:817–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zorde Khvalevsky E, Gabai R, Rachmut IH,
Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin
E, et al: Mutant KRAS is a druggable target for pancreatic cancer.
Proc Natl Acad Sci USA. 110:20723–20728. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Frémin C and Meloche S: From basic
research to clinical development of MEK1/2 inhibitors for cancer
therapy. J Hematol Oncol. 3:82010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davies SP, Reddy H, Caivano M and Cohen P:
Specificity and mechanism of action of some commonly used protein
kinase inhibitors. Biochem J. 351:95–105. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Favata MF, Horiuchi KY, Manos EJ, Daulerio
AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F,
et al: Identification of a novel inhibitor of mitogen-activated
protein kinase kinase. J Biol Chem. 273:18623–18632. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim ST, Lim H, Jang KT, Lim T, Lee J, Choi
YL, Jang HL, Yi JH, Baek KK, Park SH, et al: Impact of KRAS
mutations on clinical outcomes in pancreatic cancer patients
treated with first-line gemcitabine-based chemotherapy. Mol Cancer
Ther. 10:1993–1999. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stoletov K, Montel V, Lester RD, Gonias SL
and Klemke R: High-resolution imaging of the dynamic tumor cell
vascular interface in transparent zebrafish. Proc Natl Acad Sci
USA. 104:17406–17411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morris JP IV, Wang SC and Hebrok M: KRAS,
Hedgehog, Wnt and the twisted developmental biology of pancreatic
ductal adenocarcinoma. Nat Rev Cancer. 10:683–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X and Studzinski GP: Phosphorylation
of raf-1 by kinase suppressor of ras is inhibited by ̔MEK-specific̓
inhibitors PD 098059 and U0126 in differentiating HL60 cells. Exp
Cell Res. 268:294–300. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vaccaro V, Melisi D, Bria E, Cuppone F,
Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F and Milella
M: Emerging pathways and future targets for the molecular therapy
of pancreatic cancer. Expert Opin Ther Targets. 15:1183–1196. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
24
|
Réjiba S, Wack S, Aprahamian M and Hajri
A: K-ras oncogene silencing strategy reduces tumor growth and
enhances gemcitabine chemotherapy efficacy for pancreatic cancer
treatment. Cancer Sci. 98:1128–1136. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McCubrey JA, Steelman LS, Abrams SL,
Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati
A, et al: Emerging MEK inhibitors. Expert Opin Emerg Drugs.
15:203–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gysin S, Lee SH, Dean NM and McMahon M:
Pharmacologic inhibition of RAF→MEK→ERK signaling elicits
pancreatic cancer cell cycle arrest through induced expression of
p27Kip1. Cancer Res. 65:4870–4880. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bai X, Zhi X, Zhang Q, Liang F, Chen W,
Liang C, Hu Q, Sun X, Zhuang Z and Liang T: Inhibition of protein
phosphatase 2A sensitizes pancreatic cancer to chemotherapy by
increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis.
Cancer Lett. 355:281–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ji F, Duan HG, Zheng CQ and Li J:
Comparison of chloromethyl-dialkylcarbocyanine and green
fluorescent protein for labeling human umbilical mesenchymal stem
cells. Biotechnol Lett. 37:437–447. 2015. View Article : Google Scholar
|
